{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T20:30:43Z","timestamp":1771014643010,"version":"3.50.1"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2002,1,1]],"date-time":"2002-01-01T00:00:00Z","timestamp":1009843200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2002,1]]},"DOI":"10.1038\/sj.bjc.6600043","type":"journal-article","created":{"date-parts":[[2002,9,5]],"date-time":"2002-09-05T18:13:23Z","timestamp":1031249603000},"page":"179-184","source":"Crossref","is-referenced-by-count":73,"title":["Combination chemotherapy with or without s.c. IL-2 and IFN-\u03b1: results of a prospectively randomized trial of the Cooperative Advanced Malignant Melanoma Chemoimmunotherapy Group (ACIMM)"],"prefix":"10.1038","volume":"86","author":[{"given":"J","family":"Atzpodien","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K","family":"Neuber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D","family":"Kamanabrou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Fluck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E B","family":"Br\u00f6cker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C","family":"Neumann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T M","family":"R\u00fcnger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G","family":"Schuler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P","family":"von den Driesch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E","family":"Paul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T","family":"Patzelt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Reitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2002,2,8]]},"reference":[{"key":"BF6600043_CR1","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1200\/JCO.1994.12.8.1553","volume":"12","author":"MB Atkins","year":"1994","unstructured":"Atkins MB, O'Boyle KR, Sosman JA, Wei\u00df GR, Margolin KA, Ernest ML, Kappler K, Mier JW, Sparano JA, Fischer RI (1994) Multiinstitutional phase II trial of intensive combination chemoimmunotherapy for metastatic melanoma. J Clin Oncol 12: 1553\u20131560","journal-title":"J Clin Oncol"},{"key":"BF6600043_CR2","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1016\/0959-8049(94)00459-5","volume":"31","author":"J Atzpodien","year":"1995","unstructured":"Atzpodien J, Lopez H\u00e4nninen E, Kirchner H, Franzke A, K\u00f6rfer A, Volkenandt M, Duensing S, Schomburg A, Chaitchik S, Poliwoda H (1995) Chemoimmunotherapy of advanced malignant melanoma: sequential administration of subcutaneous interleukin-2 and interferon-\u03b1 after intravenous dacarbazine, cisplatin, carmustine and tamoxifen. Eur J Cancer 31: 876\u2013881","journal-title":"Eur J Cancer"},{"key":"BF6600043_CR3","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1097\/00008390-200104000-00015","volume":"11","author":"V Chiarion Sileni","year":"2001","unstructured":"Chiarion Sileni V, Nortilli R, Aversa SM, Paccagnella A, Medici M, Corti I, Favaretto AG, Cetto GL, Monfardini S (2001) Phase II randomized study of dacarbazine, carmustine, cisplatin and tamoxifen versus dacarbazine alone in advanced melanoma patients. Melanoma Res 11: 189\u2013196","journal-title":"Melanoma Res"},{"issue":"6 Suppl","key":"BF6600043_CR4","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1111\/1523-1747.ep12875512","volume":"95","author":"ET Creagan","year":"1990","unstructured":"Creagan ET, Schaid DJ, Ahmann DL, Fryak S (1990) Disseminated malignant melanoma and recombinant interferon: analysis of seven consecutive phase II investigations. J Invest Dermatol 95: 6 Suppl 188\u2013192","journal-title":"J Invest Dermatol"},{"key":"BF6600043_CR5","doi-asserted-by":"publisher","first-page":"1743","DOI":"10.1200\/JCO.1998.16.5.1743","volume":"16","author":"CI Falkson","year":"1998","unstructured":"Falkson CI, Ibrahim J, Kirkwood JM (1998) Phase III of dacarbazine versus dacarbazine with interferon alpha-2b versus dacarbazine with tamoxifen versus dacarbazine with interferon alpha-2b and tamoxifen in patients with metastatic melanoma: an Eastern Cooperative Oncology Group study. J Clin Oncol 16: 1743\u20131751","journal-title":"J Clin Oncol"},{"key":"BF6600043_CR6","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1097\/00008390-199508000-00011","volume":"5","author":"LG Feun","year":"1995","unstructured":"Feun LG, Savaraj N, Moffat F, Robinson D, Liebmann A, Hurley J, Raub Jr WA, Richman SP (1995) Phase II trial of recombinant interferon-alpha with BCNU, cisplatin, DTIC and tamoxifen in advanced malignant melanoma. Melanoma Res 5: 273\u2013276","journal-title":"Melanoma Res"},{"key":"BF6600043_CR7","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1038\/bjc.1998.630","volume":"78","author":"R Hoffmann","year":"1998","unstructured":"Hoffmann R, M\u00fcller I, Neuber K, La\u00dfmann S, Buer J, Probst M, Oevermann K, Franzke A, Kirchner H, Ganser A, Atzpodien J (1998) Risk and outcome in metastatic malignant melanoma patients receiving DTIC, cisplatin, BCNU and tamoxifen followed by immunotherapy with interleukin 2 and interferon alpha2a. Br J Cancer 78: 1076\u20131080","journal-title":"Br J Cancer"},{"key":"BF6600043_CR8","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1038\/bjc.1998.214","volume":"77","author":"SR Johnston","year":"1998","unstructured":"Johnston SR, Constenla DO, Moore J, Atkinson H, A'Hern RP, Dadian G, Riches PG, Gore ME (1998) Randomized phase II trial of BCDT [carmustine (BCNU), cisplatin, dacarbazine (DTIC) and tamoxifen] with or without interferon alpha (IFN-alpha) and interleukin (IL-2) in patients with metastatic melanoma. Br J Cancer 77: 1280\u20131286","journal-title":"Br J Cancer"},{"key":"BF6600043_CR9","doi-asserted-by":"publisher","first-page":"1752","DOI":"10.1200\/JCO.1998.16.5.1752","volume":"16","author":"SS Legha","year":"1998","unstructured":"Legha SS (1998) Development of a biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, dacarbazine, interferon alfa, and interleukin-2 for patients with metastatic melanoma. J Clin Oncol 16: 1752\u20131759","journal-title":"J Clin Oncol"},{"key":"BF6600043_CR10","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1093\/oxfordjournals.annonc.a010762","volume":"7","author":"SS Legha","year":"1996","unstructured":"Legha SS, Ring S, Bedikan A, Plager C, Eton O, Buzaid AC, Papadopoulos N (1996) Treatment of metastatic melanoma with combined chemotherapy containing cisplatin, vinblastine and dacarbazine (CVD) and biotherapy using interleukin-2 and interferon-alpha. Ann Oncol 7: 827\u2013835","journal-title":"Ann Oncol"},{"issue":"1 Suppl","key":"BF6600043_CR11","first-page":"9","volume":"3","author":"SS Legha","year":"1997","unstructured":"Legha SS, Ring S, Eton O, Bedikian A, Plager C, Papadopoulos N (1997) Development and results of biochemotherapy in metastatic melanoma: the University of Texas M.D. Anderson Cancer Center experience. Cancer J Sci Am 3: 1 Suppl 9\u201315","journal-title":"Cancer J Sci Am"},{"key":"BF6600043_CR12","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1200\/JCO.1994.12.3.617","volume":"12","author":"EF McClay","year":"1994","unstructured":"McClay EF, McClay ME (1994) Tamoxifen: is useful in the treatment of patients with metastatic melanoma? J Clin Oncol 12: 617\u2013626","journal-title":"J Clin Oncol"},{"key":"BF6600043_CR13","first-page":"744","volume":"23","author":"EF McClay","year":"1996","unstructured":"McClay EF, McClay ME (1996) Systemic chemotherapy for the treatment of metastatic malignant melanoma. Semin Oncol 23: 744\u2013753","journal-title":"Semin Oncol"},{"key":"BF6600043_CR14","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1054\/bjoc.1999.1056","volume":"82","author":"MR Middleton","year":"2000","unstructured":"Middleton MR, Lorigan P, Owen J, Asshcroft L, Lee SM, Harper P, Thatcher N (2000) A randomized phase III study comparing dacarbazine, BCNU, cisplatin and tamoxifen with dacarbazine and interferon in advanced melanoma. Br J Cancer 82: 1158\u20131162","journal-title":"Br J Cancer"},{"key":"BF6600043_CR15","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1200\/JCO.1992.10.12.1919","volume":"10","author":"S Pyrhonen","year":"1992","unstructured":"Pyrhonen S, Hahka-Kemppinen M, Muhonen T (1992) A promising interferon plus four-drug chemotherapy regimen for metastatic melanoma. J Clin Oncol 10: 1919\u20131926","journal-title":"J Clin Oncol"},{"key":"BF6600043_CR16","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1200\/JCO.1992.10.8.1338","volume":"10","author":"JM Richards","year":"1992","unstructured":"Richards JM, Mehta N, Ramming K, Skosey P (1992) Sequential chemoimmunotherapy in the treatment of metastatic melanoma. J Clin Oncol 10: 1338\u20131343","journal-title":"J Clin Oncol"},{"key":"BF6600043_CR17","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1001\/jama.1994.03510360033032","volume":"271","author":"JM Rosenberg","year":"1994","unstructured":"Rosenberg JM, Yang JC, Topalian SL, Schwarzentruber DJ, Web JS, Parkinson DR, Seipp CA, Einhorn JH, White DE (1994) Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin-2. JAMA 271: 907\u2013913","journal-title":"JAMA"},{"key":"BF6600043_CR18","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1200\/JCO.1999.17.3.968","volume":"17","author":"SA Rosenberg","year":"1999","unstructured":"Rosenberg SA, Yang JC, Schwartzentruber DJ, Hwu P, Marincola FM, Topalian SL, Seipp CA, Einhorn JH, White DE, Steinberg SM (1999) Prospective randomized trial of the treatment of patients with metastatic melanoma using chemotherapy with cisplatin, dacarbazine, and tamoxifen alone or in combination with interleukin-2 and interferon alfa-2b. J Clin Oncol 17: 968\u2013975","journal-title":"J Clin Oncol"},{"key":"BF6600043_CR19","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1200\/JCO.1996.14.7.2083","volume":"14","author":"JJ Rusthoven","year":"1996","unstructured":"Rusthoven JJ, Quirt IC, Iscoe NA, McCulloch PB, James KW, Lohmann RC, Jensen J, Burdette-Radoux S, Bodurtha AJ, Silver HK, Verma S, Armitage GR, Zee B, Bennett K (1996) Randomized, double-blind, placebo-controlled trial comparing the response rates of carmustine, dacarbazine, and cisplatin with and without tamoxifen in patients with metastatic melanoma. National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 14: 2083\u20132090","journal-title":"J Clin Oncol"},{"key":"BF6600043_CR20","doi-asserted-by":"publisher","first-page":"1677","DOI":"10.1002\/(SICI)1097-0142(19980501)82:9<1677::AID-CNCR13>3.0.CO;2-1","volume":"82","author":"JJ Stark","year":"1998","unstructured":"Stark JJ, Dillman RO, Schulof R, Wiemann MC, Barth NM, Honeycutt PJ, Soori G (1998) Interferon alpha and chemohormonal therapy for patients with advanced melanoma: final results of a phase I-II study for the Cancer Biotherapy Research Group and the Mid-Atlantic Oncology Program. Cancer 82: 1677\u20131681","journal-title":"Cancer"},{"issue":"1 Suppl","key":"BF6600043_CR21","first-page":"29","volume":"3","author":"JA Thompson","year":"1997","unstructured":"Thompson JA, Gold PJ, Markowitz DR, Byrd DR, Lindgren CG, Fefer A (1997) Updated analysis of an outpatient chemoimmunotherapy regimen for treating metastatic melanoma. Cancer J Sci Am 3: 1 Suppl 29\u201334","journal-title":"Cancer J Sci Am"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/6600043","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/6600043.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/6600043.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T12:40:23Z","timestamp":1684413623000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/6600043"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,1]]},"references-count":21,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2002,1]]}},"alternative-id":["BF6600043"],"URL":"https:\/\/doi.org\/10.1038\/sj.bjc.6600043","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,1]]}}}